Targeted Radiation Therapy Yields High Response Rates in Metastatic Prostate Cancer

Excerpt:

“The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.

“The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.